AGVHD
Clinical trials for AGVHD explained in plain language.
Never miss a new study
Get alerted when new AGVHD trials appear
Sign up with your email to follow new studies for AGVHD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to tame Graft-Versus-Host disease
Disease control Not yet recruitingThis study tests a new drug called Gecacitinib combined with steroids as the first treatment for moderate to severe graft-versus-host disease (aGVHD) that can occur after a stem cell transplant. The trial will enroll 25 adults who have recently received a transplant and have not …
Matched conditions: AGVHD
Phase: PHASE2 • Sponsor: Bin Gu • Aim: Disease control
Last updated May 17, 2026 08:47 UTC
-
New drug may shield transplant patients from deadly immune attack
Disease control Not yet recruitingThis study tests whether the drug ivarmacitinib can prevent acute graft-versus-host disease (aGVHD) in 32 people with blood cancers receiving a stem cell transplant from a half-matched donor. aGVHD occurs when donor immune cells attack the patient's body. The study will measure h…
Matched conditions: AGVHD
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 15, 2026 11:57 UTC